Immunovant Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Immunovant
IMVT Stock  USD 27.35  1.17  4.47%   
Analyzing historical trends in various income statement and balance sheet accounts from Immunovant's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Immunovant's valuation are summarized below:
Market Capitalization
5.3 B
Earnings Share
(2.82)
There are currently one hundred twenty fundamental trends for Immunovant that can be evaluated and compared over time across competitors. All traders should confirm Immunovant's regular fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Enterprise Value is likely to gain to about 1.4 B in 2026, whereas Market Cap is likely to drop slightly above 918.7 M in 2026.
Check Immunovant financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunovant's main balance sheet or income statement drivers, such as Depreciation And Amortization of 322.3 K, Interest Expense of 0.0 or Selling General Administrative of 93.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.0. Immunovant financial statements analysis is a perfect complement when working with Immunovant Valuation or Volatility modules.
  
Build AI portfolio with Immunovant Stock
Check out the analysis of Immunovant Correlation against competitors.
For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.

Immunovant Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets937.3 M892.7 M277.5 M
Slightly volatile
Other Current Liabilities61.6 M58.7 M18.1 M
Slightly volatile
Total Current Liabilities83 M79.1 M24.4 M
Slightly volatile
Accounts Payable21.3 M20.3 M5.8 M
Slightly volatile
Common Stock Shares Outstanding93.2 M174.3 M59.7 M
Slightly volatile
Liabilities And Stockholders Equity937.3 M892.7 M277.5 M
Slightly volatile
Other Current Assets61.8 M58.9 M14.4 M
Slightly volatile
Total Liabilities83 M79.1 M24.6 M
Slightly volatile
Total Current Assets927 M882.8 M275.3 M
Slightly volatile
Short and Long Term Debt Total83.8 K88.2 K782.3 K
Pretty Stable
Property Plant And Equipment Net1.4 M1.1 M691.5 K
Slightly volatile
Cash427.5 M821.1 M233.6 M
Slightly volatile
Non Current Assets Total10.3 M9.8 M2.3 M
Slightly volatile
Non Currrent Assets Other9.2 M8.8 M3.4 M
Slightly volatile
Cash And Short Term Investments427.5 M821.1 M233.6 M
Slightly volatile
Net Receivables4.5 M2.9 M3.5 M
Pretty Stable
Common Stock Total Equity8.9 K14.9 K5.4 K
Slightly volatile
Non Current Liabilities Total938.8 K988.2 K1.4 M
Pretty Stable
Capital Surpluse556.3 M1.1 B353.4 M
Slightly volatile
Deferred Long Term Liabilities210.3 K221.4 K744.9 K
Slightly volatile
Net Invested Capital415.4 M813.6 M227.9 M
Slightly volatile
Short and Long Term Debt240 K270 K294.7 K
Slightly volatile
Capital Stock11 K18.4 K6 K
Slightly volatile
Short Term Debt83.8 K88.2 K576.2 K
Very volatile
Common Stock11 K18.4 K6 K
Slightly volatile
Property Plant Equipment216.3 K382.9 K157.7 K
Slightly volatile
Property Plant And Equipment Gross1.2 M847.8 K699.1 K
Slightly volatile
Non Current Liabilities Other40.2 K42.3 K1.5 M
Slightly volatile

Immunovant Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization322.3 K339.3 K64.4 M
Slightly volatile
Selling General Administrative93.3 M88.8 M28.9 M
Slightly volatile
Other Operating Expenses529.1 M503.9 M198.1 M
Slightly volatile
Research Development435.8 M415.1 M171.2 M
Slightly volatile
Total Operating Expenses529.1 M503.9 M198.1 M
Slightly volatile
Selling And Marketing Expenses197.5 K207.9 K1.5 M
Slightly volatile
Cost Of Revenue557.7 K339.3 K309.9 K
Slightly volatile
Reconciled Depreciation455.2 K433.6 K123 K
Slightly volatile
Non Recurring8 M9 M9.8 M
Slightly volatile

Immunovant Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation59.8 M56.9 M18.6 M
Slightly volatile
Depreciation270.3 K433.6 K161.2 K
Slightly volatile
Total Cash From Financing Activities308.8 K325 K162.1 M
Pretty Stable
Change To Netincome39 M37.1 M14.9 M
Slightly volatile
Sale Purchase Of Stock27.3 K28.8 K38.6 M
Pretty Stable
End Period Cash Flow428.6 M821.1 M237.2 M
Slightly volatile
Change To Inventory373.4 K685.4 K286.4 K
Slightly volatile
Begin Period Cash Flow369.1 M730.7 M186.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Average Payables454.3 K511.1 K557.9 K
Slightly volatile
Capex To Depreciation2.122.323.5021
Slightly volatile
Payables Turnover0.01410.01590.0173
Slightly volatile
Cash Per Share2.724.241.8191
Slightly volatile
Days Payables Outstanding16.5 K18.6 K20.3 K
Slightly volatile
Income Quality0.941.040.9039
Pretty Stable
Current Ratio7.5510.055.5085
Slightly volatile
Debt To Equity2.0E-42.0E-46.4719
Slightly volatile
Capex Per Share0.00470.00450.0033
Very volatile
Interest Debt Per Share7.0E-47.0E-40.0265
Very volatile
Debt To Assets1.0E-41.0E-40.3948
Slightly volatile
Days Of Payables Outstanding16.5 K18.6 K20.3 K
Slightly volatile
Ebt Per Ebit1.11.081.0098
Slightly volatile
Total Debt To Capitalization2.0E-42.0E-40.4923
Slightly volatile
Debt Equity Ratio2.0E-42.0E-46.4719
Slightly volatile
Quick Ratio7.5510.055.5085
Slightly volatile
Net Income Per E B T0.80.90.9832
Slightly volatile
Cash Ratio8.229.345.6689
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9839
Slightly volatile
Debt Ratio1.0E-41.0E-40.3948
Slightly volatile

Immunovant Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap918.7 M1.7 B1 B
Slightly volatile
Enterprise Value1.4 B1.4 B841.5 M
Slightly volatile

Immunovant Fundamental Market Drivers

Immunovant Upcoming Events

2nd of February 2024
Upcoming Quarterly Report
View
27th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

About Immunovant Financial Statements

Immunovant shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Immunovant investors may analyze each financial statement separately, they are all interrelated. The changes in Immunovant's assets and liabilities, for example, are also reflected in the revenues and expenses on on Immunovant's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-24 M-22.8 M
Cost Of Revenue339.3 K557.7 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY